Jul 19, 2022
Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.
Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor...
Jul 19, 2022
Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.
Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor...
Jul 13, 2022
Dr. Judy Chou is the President and CEO of AltruBio which is developing novel immunomodulators to treat immunological diseases such as autoimmune and inflammatory diseases. Their first-in-class agnostic antibody has a unique mechanism to regulate T cell homeostasis. Currently, there is a clinical trial for SR-aGVHD,...
Jul 13, 2022
Dr. Judy Chou is the President and CEO of AltruBio which is developing novel immunomodulators to treat immunological diseases such as autoimmune and inflammatory diseases. Their first-in-class agnostic antibody has a unique mechanism to regulate T cell homeostasis. Currently, there is a clinical trial for SR-aGVHD,...
Nov 29, 2021
Boro Dropulić is the Co-Founder and Executive Director of Caring Cross, a 501 (c)(3) non-profit dedicated to accelerating the development and manufacturing of advanced medicines to improve access to cures for all patients independent of where they live.
Boro explains, "One way to reduce the cost is by manufacturing the...